TiNi drug market is booming, many pharmaceutical companies are competing for it

[market analysis of www.chinapharma.com] TiNi, or tyrosine kinase inhibitors (PTKs), is a small molecule protein kinase inhibitor It has the function of blocking one or more protein kinases At present, most of the products are antineoplastic drugs However, fqtinib, which was first evaluated by Hutchison Whampoa pharmaceutical, is a highly selective oral vascular endothelial growth factor receptor (VEGFR) inhibitor Targeting VEGFR kinase family, it can effectively inhibit tumor metastasis and tumor angiogenesis It has many advantages, such as low toxicity, good drug tolerance and strong effect Recently, CDE officially announced the 22nd batch of drugs to be included in the priority review process, which was in the list of fuquinotinib of Huangpu pharmaceutical And just a few days later, the 23rd batch of drugs to be included in the priority review process also showed tinib drugs In fact, TiNi drugs have always been highly sought after by domestic and foreign pharmaceutical companies, and their products have been innovated, and even there has been the saying of "TiNi explosion" At present, there are 12 kinds of common TiNi products on the market in China, including imatinib, gefitinib, and exetinib Among them, exetinib and apatinib are independent brands in China Their emergence has broken the situation of Western tinib drug monopoly market Hutchison Whampoa is an innovative biopharmaceutical company based in China and facing the world Founded in 2002, the company focuses on the research and development of innovative drugs for cancer and autoimmune diseases At present, the company has a number of products under research It is worth mentioning that more than half of the new drugs developed by Hutchison Whampoa are TiNi products TiNi, or tyrosine kinase inhibitors (PTKs), is a small molecule protein kinase inhibitor It has the function of blocking one or more protein kinases At present, most of the varieties are antineoplastic drugs In 2002, Novartis developed the world's first Tinian drug, gliclavic (imatinib mesylate), which landed in China and became a drug for the treatment of chronic myeloid leukemia as soon as it went on the market Because of its wide anti-cancer spectrum, high targeting, significant curative effect, small adverse reactions and many other clinical advantages, the whole TiNi drugs have gradually become the first-line drugs in the treatment of various tumors This time, fiquitinib, which was first evaluated by Hutchison Whampoa medicine, is a highly selective oral vascular endothelial growth factor receptor (VEGFR) inhibitor, targeting VEGFR kinase family, which can well inhibit tumor metastasis and tumor angiogenesis, and has many advantages such as low toxicity, good drug tolerance and strong effect The drug, developed by Hutchison Whampoa independently, is a molecular targeted anticancer drug with full intellectual property rights It is also a 100% domestic drug developed by local Chinese pharmaceutical companies first, launched clinical research in Chinese patients and jointly developed by local Chinese researchers The indications of fiquitinib currently under study include colorectal cancer, lung cancer and advanced gastric cancer According to the data of minenet, anti-tumor chemicals are divided into 9 categories: anti metabolism drugs, plant alkaloids and other natural drugs, monoclonal antibodies, protein kinase inhibitors, platinum compounds, cytotoxin antibiotics and related substances, alkylating agents, anti-tumor therapeutic antidotes and other anti-tumor drugs Among them, the vast majority of protease inhibitor anti-tumor drugs are TiNi anti-tumor drugs In 2016, the sales volume of China's public medical terminals (including urban public hospitals, county-level public hospitals, urban community centers, township hospitals) reached 6.63 billion yuan, an increase of 15.59% year-on-year, ranking fourth in the pattern of anti-tumor chemicals, with a market share of 11.57% Imatinib: imatinib, a commercial name of greavel, is divided into four enterprise markets The original manufacturer is Novartis, which entered the Chinese market in 2002 The indications are chronic myeloid leukemia and malignant gastrointestinal stromal tumor In April 2013, the protection of imatinib, the original research drug of Novartis, expired in China, and then domestic imatinib began to seize the market Imatinib tablet of Jiangsu Haosen Pharmaceutical Group was listed in 2013 with the trade name of Xinwei; imatinib capsule of Zhengda Tianqing Pharmaceutical Group was listed in 2014 with the trade name of genico; subsequently imatinib tablet of stone Pharmaceutical Group was also listed with the trade name of nolinin According to the data of mienei.com, in 2016, the market sales of imatini, the terminal of public medical institutions in China, was 1.92 billion yuan, up 9.17% year on year Among them, Novartis accounted for 80.29%, Jiangsu Haosen for 10.97%, Zhengda Tianqing for 8.53% and Ouyi for 0.21% Gefitinib: the sales of gefitinib decreased The trade name is IRESSA The original manufacturer is AstraZeneca It entered the Chinese market in 2005 The indication is advanced or metastatic non-small cell lung cancer It is a lung cancer targeting drug of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in the global lung cancer field In recent years, the sales volume of gefitinib has been declining year by year, and it has entered the position of "taking volume at a reduced price" According to the data of mienei.com, in 2016, the sales volume of gefitinib terminal of public medical institutions in China was 1.23 billion yuan, down 2.28% year on year As gefitinib enters the new medical insurance catalogue through the first batch of drug price negotiations of the national health and Family Planning Commission, it will achieve the result of taking volume at a reduced price, which will promote the market growth of gefitinib In addition, on February 18 of this year, the domestic gefitinib developed by Qilu Pharmaceutical Co., Ltd was also listed under the trade name of IRICO, breaking the monopoly situation of the original research drug Irisa of AstraZeneca Exetane, apatini: the pride of domestic medicine exetane, trade name Kemena, is a small molecule targeted anti-tumor drug with completely independent intellectual property rights in China, developed and produced by Beida Pharmaceutical Co., Ltd., with indications for the treatment of advanced non-small cell lung cancer The emergence of exinib broke the monopoly of Western drug market According to the data of mienei.com, in 2016, the sales volume of China's public medical institutions terminal exinib was 740 million yuan, an increase of 17.65% year on year The domestic market scale of exetinib has exceeded 1 billion yuan, and it is expected that in 2017, exetinib will become a small molecule targeted drug market for lung cancer Apatinib, trade name is aitan, a national class 1.1 small molecule targeted new drug independently developed by Hengrui medicine, was approved by CFDA for listing in October 2014 and used for clinical treatment of advanced gastric cancer, while multiple indications such as lung cancer and liver cancer are also expanding According to the data of mienei.com, in 2016, the sales volume of apatini terminal in China's public medical institutions was 310 million yuan, an increase of 19.64% year on year Lapatinib: the growth rate of lapatinib is more than 2 times, and its trade name is Talisa The original manufacturer is GlaxoSmithKline It entered the Chinese market in 2013, and its indication is advanced or metastatic breast cancer According to the data of mienei.com, in 2016, the sales volume of lapatinib terminal in public medical institutions in China was 27.33 million yuan, an increase of 243.14% year on year At present, Nanjing Xiansheng, Sichuan Kelun, Qilu pharmaceutical, Zhengda Tianqing pharmaceutical, Shandong Luoxin pharmaceutical and many other enterprises are carrying out the research and development of generic drugs of this product Conclusion: TiNi is a small molecule targeted drug, which is an important group of anti-tumor clinical drugs, and also a new variety after entering the new century It has the advantages of high targeting, significant efficacy, less adverse reactions and so on It has become the future trend of clinical medicine, and the variety that enterprises are chasing However, there are also problems in the research and development of TiNi group This kind of drugs has the characteristics of high concentration of market share, forming a pattern of monopoly varieties of advantageous enterprises Therefore, in order to stand out from so many TiNi drugs, it is necessary to find out the difference in clinical efficacy! Original title: TiNi anti-tumor drugs are popular in the market, and the "domestic team" is not willing to lag behind, striving to catch up!